n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, June 6th, 2016

The QualityStocks
Daily Stock List

graphic
graphic

Raadr, Inc. (RDAR)

Epic Stock Picks, Wolf of Penny Stocks, First Penny Picks, StocksImpossible, OTCBB Journal, Penny Stock Hub, TheNextBigTrade, DSR News, BestDamnPennyStocks, Juicy Penny Stocks, Penny Stock Titans, StockMister, 1-2-3 Stock Alerts, and Penny Stock Circle reported earlier on Raadr, Inc. (RDAR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Raadr, Inc. is a technology and software development company. It monitors cyber bullying and social media platforms via its artificial intelligent proprietary web-based application. The Company is the maker of the artificial intelligent proprietary technology application RAADR©. It has developed a web-based tool, which provides families with peace of mind when it comes to knowing that children are safe from bullying and predatory behavior. Raadr has its corporate headquarters in Phoenix, Arizona.

The Company’s core competency focuses on building and acquiring apps and other products, services, and companies. This is to build a nationwide network of related businesses that are positioned to serve the mobile app development needs of small businesses and individuals.

Through customizing their own innovative monitoring and alert settings, parents and guardians can be alerted when their children’s Facebook, Twitter, Instagram and other relevant social media platforms under scrutiny become posted with unsuitable language.

Through using customized keywords selected by the user, which are added to an already existing database, parents and guardians can carry a sense of confidence that the youth are safe and acting in a fun, while suitable manner. RAADR© gives families the ability to protect their image, fight wrong postings, and for individuals, safeguard their children from online bullying.

RAADR© monitors different social networks continually. It alerts one to any keywords that might raise an issue. RAADR© can help identify who one’s child is interacting with online.

In addition, RAADR© is accessible on multiple platforms. Its platform also provides a third tool: the Company has designed a facial recognition engine. This engine detects a child and monitors any new usernames, accounts, or aliases they create in an attempt to circumvent the monitoring systems. In essence, RAADR© helps one take the heartbeat of what is happening online for their child and for the community around their child.

Last month, Raadr announced it received approval from Apple for its BullyRAADR iOS application, on May 6, 2016. This is the second full-featured child protection application Raadr has on Apple’s app store for iOS devices. The first app it launched was focused towards parents to help them monitor their children’s online activity for red flags. This application is focused towards children. It will allow them to directly report bullying incidents to school officials and parents.

Raadr, Inc. (RDAR), closed Monday's trading session at $0.0004, down 33.33%, on 3,726,825 volume with 15 trades. The average volume for the last 60 days is 4,088,405 and the stock's 52-week low/high is $0.0005/$0.398.

Neurotrope, Inc. (NTRP)

SmallCapVoice reported earlier on Neurotrope, Inc. (NTRP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed Neurotrope, Inc. is a specialty biopharmaceutical company. Neurotrope Bioscience, Inc. is the operating subsidiary of Neurotrope, Inc. Neurotrope Bioscience was established in October of 2012 mainly to license, develop, and commercialize various novel therapeutic and diagnostic technologies from the Blanchette Rockefeller Neuroscience Institute (BRNI) centered on the development of conventional small molecules, which are extraordinarily potent in the activation of the enzyme PKCe. Neurotrope is headquartered in Newark, New Jersey.

The scientific foundation of Neurotrope’s treatment is activation of Protein Kinase C isozymes ε and α by bryostatin, a natural product that can result in enhancement of existing synapses, reduces toxic amyloid generation, promotes synaptogenesis, and enhances memory and learning, thus having the potential to improve cognitive function in Alzheimer's disease.

Neurotrope has commenced its Phase 2b clinical trial in 150 moderately severe to severe Alzheimer's patients. The Company is also conducting preclinical studies of bryostatin as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease. These are two rare genetic diseases for which only symptomatic treatments are now available. The Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neurotrope for bryostatin as a treatment for Fragile X Syndrome.

Neurotrope has exclusive licensed technology from the Blanchette Rockefeller Neurosciences Institute for Alzheimer's disease and Fragile X Syndrome, has a global, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease, and is partnered with Stanford University to synthesize and find the next generation bryostatin – called bryologs.

This past March, Neurotrope announced that its lead Alzheimer's drug Bryostatin improved disease symptoms and restored normal synaptic networks in a young transgenic animal model of Fragile X Syndrome (FXS) - a common genetic cause of mental retardation and autism.  The study was led by scientists at the Blanchette Rockefeller Neuroscience Institute (BRNI). It demonstrated that chronic treatment with bryostatin-1 rescues young fragile X mice (corresponding to 15 – 16-year-old children) from the disorder phenotypes.

Last month, Neurotrope announced that it entered into a research collaboration with the International Rett Syndrome Foundation, DBA: Rettsyndrome.org, to explore the potential of Bryostatin for the treatment of Rett syndrome. Rett syndrome is a rare non-inherited genetic postnatal neurological disorder. It occurs almost exclusively in between 1:10,000 to 1:15,000 live female births and leads to lifelong impairments.

Neurotrope, Inc. (NTRP), closed Monday's trading session at $0.425, down 7.61%, on 3,000 volume with 2 trades. The average volume for the last 60 days is 9,943 and the stock's 52-week low/high is $0.20/$1.00.

White Mountain Titanium Corp. (WMTM)

MoneyTV and Penny Stock Chaser reported earlier on White Mountain Titanium Corp. (WMTM), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

White Mountain Titanium Corp. is a mineral exploration company. It engages in the search for mineral deposits or reserves that could be economically and legally extracted or recovered. It holds mining concessions covering two rutile properties situated in the Atacama region (Region III) of northern Chile, specifically Cerro Blanco and the newly discovered La Martina. The Company’s main business is to explore for and develop natural rutile deposits on its mining concessions. Additionally, it plans to expand its exploration activities on the La Martina concessions which it discovered in 2013. White Mountain Titanium is based in Santiago, Chile.

The Company holds mining concessions on the Cerro Blanco property. The property consists of 41 registered mining exploitation concessions and 34 mining exploration concessions in the process of being constituted, over roughly 17,041 hectares positioned approximately 39 kilometers west of the City of Vallenar in the Atacama, or Region III, geographic region of northern Chile. The Cerro Blanco project received full environmental approval from governmental authorities on May 22, 2015.

White Mountain Titanium continues to fund R&D on the Chinuka Process, which is conducting research into the recovery of feldspar and the production of refined titanium metal from materials sourced from these mining concessions. Work continues to investigate the commercial viability of producing a feldspar co-product. The Company indicates that feldspar could find applications in the glass and ceramics industries.

White Mountain earlier signed a Letter of Intent (LOI) with Nexo Capital Partners, LLC to fund, construct, and manage a desalination plant, which forms part of the Company’s Cerro Blanco mining project. NEXO is a U.S. private equity firm. NEXO specializes in the business development of new technologies through strategic project acquisition and technology-implementation opportunities.

NEXO’s plan is to use the services of an innovative U.S. water technology company based in Boston, Massachusetts.  Through incorporating the proven water technology of this company into the desalination design at Cerro Blanco, the parties intend to substantially increase the fresh water recovery over that achievable through reverse osmosis alone.

This past March, White Mountain Titanium announced the completion of a $2,000,000 debt funding agreement with NEXO WMTM Holdings, LLC, a subsidiary of NEXO Capital Partners. With this Loan Agreement dated and entered into on March 16, 2016, the Company borrowed $2,000,000 from NEXO - evidenced by a 7 percent Senior Convertible Promissory Note.

White Mountain Titanium Corp. (WMTM), closed Monday's trading session at $0.08, even for the day. The average volume for the last 60 days is 15,800 and the stock's 52-week low/high is $0.07/$0.46.

Avant Diagnostics, Inc. (AVDX)

StockToBuyNow and Tip.us reported earlier on Avant Diagnostics, Inc. (AVDX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Avant Diagnostics, Inc. is a molecular diagnostics company listed on the OTC Bulletin Board. The Company specializes in biomarker tests being developed in the areas of oncology and neurology. It is developing specialized tests that are pioneering in medical testing and its OvaDx® Pre-Symptomatic Ovarian Cancer Screening Test is a leading innovation in commercializing these tests. Avant Diagnostics is headquartered in Scottsdale, Arizona.

The Company has patented its manufacturing technology and its OvaDx® markers and kits are proprietary. Moreover, Avant is developing OvaDx® for use in monitoring women diagnosed previously with ovarian cancer. OvaDx® is a sophisticated microarray-based test. OvaDx® measures the activation of the immune system in blood samples in response to ovarian tumor cell development.

Avant Diagnostics is the foremost developer of proteomic technologies for measuring the activation status of key signaling pathways across numerous different cancer types, including breast, ovarian, and pancreatic, which are instrumental in the development of companion diagnostics for molecular-targeted therapies.

The Company provides personalized medicine diagnostic testing capabilities via its TheraLink® Diagnostic Assays, chiefly for breast cancer, to assist clinical oncologists in identifying likely responders for approximately 30 Food and Drug Administration (FDA)-approved drug treatment regimens by way of its CLIA/CAP.

Avant Diagnostics has its neurology division. This division owns the rights to MSPrecise™, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive global license to the Lymphocyte Proliferation test (LymPro Test™) for Alzheimer's disease, developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property (IP) for the diagnosis of Parkinson's disease (NuroPro).

Recently, Avant Diagnostics announced the acceptance of two posters for presentation at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting taking place June 3-7, 2016 in Chicago, Illinois.

Mr. Glenn D. Hoke, PhD, incoming Chief Scientific Officer at Avant Diagnostics, said, “We look forward to presenting this important work that was completed with leading clinical collaborators, demonstrating the power of our reverse phase protein array (RPPA) pathway analysis technology.”

In addition, Avant Diagnostics recently announced it completed the acquisition of Amarantus Diagnostics, Inc. (AMDX), a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc. (AMBS), and the business of Theranostics Health, Inc. (THI). With the agreement for the acquisition of AMDX, Avant has acquired all of the outstanding shares of common stock of AMDX for a total of 80,000,000 shares of Avant Diagnostics common stock, subject to issuance of additional shares upon the occurrence of certain future events.  With the agreement for the acquisition of THI, Avant acquired the assets and operations of THI for a total of 25,000,000 shares of Avant Diagnostics common stock.

Avant Diagnostics, Inc. (AVDX), closed Monday's trading session at $0.40, up 12.96%, on 10,525 volume with 9 trades. The average volume for the last 60 days is 51 and the stock's 52-week low/high is $0.20/$0.7241.

Delta International Oil & Gas, Inc. (DLTZ)

Today we are reporting on Delta International Oil & Gas, Inc. (DLTZ), here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Delta International Oil & Gas, Inc. is a global company specializing in energy. It holds interests in exploratory oil and gas blocks in Argentina and explores them by way of joint ventures (JVs). The Company’s investment in MHD Technology Corp. helps extend Delta's reach in the energy field. MHD Technology is a New York company, which works to apply its patented technology in MagnetoHydroDynamics to water pipelines in the continental United States. Delta International Oil & Gas is based in Scottsdale, Arizona.

An independent oil and gas company, Delta engages in oil and gas acquisition and exploration activities in Argentina. The Company’s operating policies have been to secure oil and gas properties and concessions that are either producing economical quantities of oil and gas or which demonstrate favorable characteristics for well "workovers" with a history of first-rate production.

Delta is presently evaluating prospects for investments in fields other than oil and gas exploration and production. Recently, Delta International Oil & Gas announced its acquisition of a 10 percent interest in MHD Technology Corp. via its wholly-owned subsidiary Neptune Industries LLC. MHD Technology is developing an innovative water transportation and desalination technology.  MHD's next steps are to perform a simulation of its product and subsequently to build the first prototype. Delta's subsidiary, Neptune Industries, will initially be involved in both of these steps and also in some administrative capacity.

Regarding Delta’s oil and gas investments, as of March 31, 2016, it, via South American Hedge Fund LLC (SAHF), retained 18 percent of the total concession in the carryover mode (no cost obligations to SAHF) in the Tartagal and Morillo oil and gas concessions in Northern Argentina. Delta International Oil & Gas does not operate the Tartagal and Morillo concession; it has a minority position in the JV.

Moreover, Delta holds a 30.6 percent interest in the Valle de Lerma concession in Northern Argentina. The JV partners are Grasta SA, PetroNEXUS, High Luck Group, and REMSA. Delta is looking to sell its full stake in Valle de Lerma. As of May 13, 2016, Delta International Oil & Gas and New Times Energy Corp. Limited reached an agreement for Delta’s sale of its 18 percent interest in Tartagal and Morillo for a total consideration of US$4 million. There are contingencies in the agreement. The two companies have 30 days to sign a final contract.

Delta International Oil & Gas, Inc. (DLTZ), closed Monday's trading session at $0.021, down 75.69%, on 16,700 volume with 2 trades. The average volume for the last 60 days is 5,352 and the stock's 52-week low/high is $0.0101/$0.16.

graphic

The QualityStocks
Company Corner

graphic
graphic

Agora Holdings, Inc. (AGHI)

The QualityStocks Daily Newsletter would like to spotlight Agora Holdings, Inc. (AGHI). Today, Agora Holdings, Inc. closed trading at $0.15312, off by 2.28%, on 44,141 volume with 19 trades. The stock’s average daily volume over the past 60 days is 168,586, and its 52-week low/high is $0.03/$2.50.

Agora Holdings, Inc. announced today that BF Borgers CPA PC has completed the audit of its fiscal years ended December 31, 2015 and 2014. The audited findings will be posted shortly to Agora's filings on OTC Markets. The review engagement for the interim report for the three months ended March 31, 2016 is underway and is expected to be completed shortly and both files will be posted concurrently so that the Company has all current reports filed. The Company is proud to announce this milestone as it moves to become a fully reporting company. Audited financial statements and periodic reports will now be regularly posted for Agora on the OTC Markets site.

Agora Holdings, Inc. (AGHI), together with its wholly-owned subsidiary, Geegle Media, is leading a diversified family entertainment and media enterprise through business segments which include: TV on Demand, interactive media, business products and consumer platforms. With its multi-dimensional approach, Geegle Media supports Agora Holdings' mission to deliver innovate and high-quality business solution products and to deliver video content from around the world.

Geegle Media web platforms include; GeegleTV, Frame, 1000Salads, RealtyTV and LobbyTV. Geegle TV is a multi-platform video entertainment website that curates high-quality video content from around the world. In 2016, GeegleTV will serve as co-producer by airing original content. By exposing undiscovered content to millions of users and rendering it shareable to social media, Geegle TV will serve as a marketing partner to local and internationally based TV shows not yet on the open market.

For commercial use, Geegle Media provides a variety of solutions that include web development and billing software for VoIP applications. RealtyTV is its state-of-the-art platform for real estate brokerages. LobbyTV is another of its widely used products by business offices. For individuals, Geegle TV combines radio, On Demand movies, news, sports and children's content.

Geegle Media is also developing 1000salads, an online hub that encourages healthy lifestyles. The portal will feature recipes and products, health-oriented articles and a curated selection of local restaurants and grocers that deliver to the health-conscious user. Currently in its alpha stage of development, 1000salads is gearing up its sales and marketing in preparation for its launch in 2016.

Geegle Media differs from other On Demand providers, such as Netflix and HBO, in that its service is free of constraints such as subscription, fees and penalties. As consumers increasingly opt for personalized sources of entertainment, Agora recognizes the vast opportunities and growth potential provided by the rising popularity of TV On Demand. The company also benefits from strong and visionary management with a track record of bringing innovative ideas to fruition. Disclaimer

Agora Holdings, Inc. Company Blog

Agora Holdings, Inc. News:

Agora Holdings Inc. Audit Is Complete, Company Continuing to Progress Its Plans to Move Up the Board to QB Level

Agora Holdings, Inc. Updates Shareholders on FRAME Technology, Accounting Audit

Agora Holdings Inc. Signs Engagement Letter With Auditing Firm, BF Borgers CPA PC

Cherubim Interests, Inc. (CHITD)

The QualityStocks Daily Newsletter would like to spotlight Cherubim Interests, Inc. (CHITD). Today, Cherubim Interests, Inc. closed trading at $0.15, up 361.54%, on 2,495 volume with 6 trades. The stock’s average daily volume over the past 60 days is 46, and its 52-week low/high is $0.0325/$1,200.00.

Cherubim Interests, Inc. (CHITD) is a development-stage alternative construction and real estate development company seeking various opportunities relative to the company's management team of experts in property management, construction and finance.

The company's primary focus is within the real estate development and controlled environment agriculture sectors, which Cherubim recently entered into by acquiring an exclusive worldwide license for the deployment of a proprietary plant cultivation technology. Through its wholly owned subsidiary, BudCube Cultivation Systems USA, Cherubim plans to construct, deploy and lease scalable medical and recreational marijuana cultivation facilities for commercial applications.

Coupled with a real estate development and property management business model, BudCube Cultivation Systems ("BCS") can position itself anywhere in the world where the cultivation of cannabis is legal. BCS's unique business model positions the company to greatly benefit as more market participants seek to gain entry into a fast-growing market at an attractive price point.

Armed with the ability to lease a portable and scalable turn-key cultivation solution to growers, Cherubim aims to use its licensed solution to fill the gap for both first-time and experienced cultivators who may not have the capital resources to buy land, construct or tenant-improve existing structures for the optimum environment for developing a high-quality cannabis product. Disclaimer

Cherubim Interests, Inc. Company Blog

Cherubim Interests, Inc. News:

Cherubim Interests, Inc. Acquires Victura Roofing and Cherubim Builders Group Oklahoma

Moving Ahead of Averages, Technical Review -- Research on Saleen Automotive, Cherubim Interests, Fission Uranium, and Pure Biosciences

Cherubim Interests, Inc. Signs MOU to Acquire Revenue-Producing Company

Alternet Systems, Inc. (ALYI)

The QualityStocks Daily Newsletter would like to spotlight Alternet Systems, Inc. (ALYI). Today, Alternet Systems, Inc. closed trading at $0.0032, up 6.67%, on 7,800 volume with 2 trades. The stock’s average daily volume over the past 60 days is 151,847, and its 52-week low/high is $0.003/$0.029.

Alternet Systems, Inc. (ALYI) invests in and partners with companies that are creating the future of money in the high growth, emerging technology fields of digital commerce, multichannel payments, and predictive analytics.

Vision: Be the leading digital commerce, multichannel payments, predictive analytics solutions provider into global markets

Mission: To provide innovative solutions that facilitates and expedites commerce, enriching our partners and their customers' experience, and improving efficiency. Recognizing that the world is becoming increasingly dependent on technological conveniences, Alternet Systems aims to provide its customers with the tools to prepare themselves for a new era of digital commerce and payments, financial services and consumer information, and, most importantly, a new era of how to live.

Since 2010, Alternet has maintained a progressive focus on the high-growth, mobile value-added service industries of mobile financial services and mobile security. In 2014, the company expanded its scope of expertise to include in its investment verticals the exciting digital commerce space, transforming the legacy electronic payments infrastructure and developing advanced predictive data analytics applications for the mass consumer, telecommunications and financial industry.

With strategic investments in these three key, high-growth markets, Alternet is accelerating the future of money and its role in the global demand for these services. The company is guided by a team of executives specializing in entrepreneurial endeavors, innovation, corporate strategy, financial and executive management of multi-national organizations, and a vast network of industry resources.

As Alternet embarks on this new path, the company will be led by a management team and board of directors with over a century's worth of combined experience in the fields of investing, technology, and financing, and the consensus knowledge of where to invest and when in start-up and early-stage companies. Disclaimer

Alternet Systems, Inc. Company Blog

Alternet Systems, Inc. News:

Alternet Systems Data Analytics Solution Gains Momentum with New Clients and Partners

Alternet Systems Announces Caprock Research Report with Near Term Price Target of $0.05 and 'Accumulate' Recommendation

Alternet Systems Launches Data Analytics Division To Build On Existing Revenue Base

OurPet's Company (OPCO)

The QualityStocks Daily Newsletter would like to spotlight OurPet's Company (OPCO). Today, OurPet's Company closed trading at $0.9485, up 4.23%, on 200 volume with 1 trade. The stock’s average daily volume over the past 60 days is 5,659, and its 52-week low/high is $0.60/$1.06.

OurPet's Company (OPCO) develops, produces and markets various pet accessory and consumable products designed to awaken pets' natural instincts, be it in feeding, playing or waste management. Sold globally through pet specialty retailers, food, drug and mass chains, e-commerce and international channels, the company's products are marketed under a the OurPets®, Pet Zone® and PetTastic® brands with well-known sub-brands such as Play-N-Squeak™, Cosmic Catnip™, Durapet, SmartScoop and Flappy. In total, OurPet's has an intellectual property portfolio featuring more than 160 individual patents, giving the company sustainable access to the pet products industry for the foreseeable future.

In recent years, the U.S. pet products and services market has experienced strong growth, with total sales accounting for approximately $73 billion in 2014, according to a report by Packaged Facts. In 2015, this strong performance is expected to continue, building on the recent rise in related ecommerce purchases, as well as an uptick in dog and cat ownership throughout the country. In order to capitalize on this market performance, OurPet's maintains an ongoing new product development program to continually keep an evolutionary and revolutionary new product pipeline feeding its offerings. In July 2015, OurPet's introduced many new products at the national Super Zoo trade show in Las Vegas such as the Catty Whack®, Designer Diner™/Barking Bistro™ and the Zoom Plume™.

The company's capitalization strategy is guided by a management team of experienced industry professionals dedicated to further strengthening its product portfolio through aggressive development of innovative products. Management has a proven track-record of leveraging deep knowledge in the innovation, technology, distribution and pet markets to successfully push through adverse market conditions to achieve increases in revenue, margins and net income.

OurPet's, through its innovative and extensive line of popular pet products, is in a favorable strategic position to continue building upon its recent market growth. For prospective shareholders, this positioning makes the company an intriguing investment opportunity in the months to come. Look for OurPet's to capitalize on steady market performance moving forward, providing an opportunity for the company to realize strong investor returns in the future. Disclaimer

OurPet's Company Company Blog

OurPet's Company News:

OurPet's Company Sponsors 65th Annual BetterInvesting National Convention

OurPetís Company Reports Record 2016 First Quarter Results

Ourpet's Company Reaches a Settlement With Competitor Over Durapet(R) Patents

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $2.32, up 0.43%, on 3,596 volume with 11 trades. The stock’s average daily volume over the past 60 days is 6,400, and its 52-week low/high is $1.25/$7.50.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.

The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.

In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation Announces Publication of Preclinical Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation

Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation's Phase I Clinical Trial for the Treatment of Parkinson's Disease

International Stem Cell Corporation Announces Operating Results for the Three-Months Ended March 31, 2016

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

QualityStocks
(CHITD)

2.

Penny Stock Newsletter
(COLV)

3.

Profitable Trader Authority
(GRSO)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251